100 related articles for article (PubMed ID: 34214676)
1. Proteomic profiling the molecular signatures of plectranthoic acid in prostate cancer cells.
Akhtar N; Abbasi SW; Rubnawaz S; Jafri L; Rani R
J Proteomics; 2021 Aug; 246():104311. PubMed ID: 34214676
[TBL] [Abstract][Full Text] [Related]
2. Targeting epithelial to mesenchymal transition in prostate cancer by a novel compound, plectranthoic acid, isolated from Ficus microcarpa.
Akhtar N; Syed DN; Lall RK; Mirza B; Mukhtar H
Mol Carcinog; 2018 May; 57(5):653-663. PubMed ID: 29436741
[TBL] [Abstract][Full Text] [Related]
3. The pentacyclic triterpenoid, plectranthoic acid, a novel activator of AMPK induces apoptotic death in prostate cancer cells.
Akhtar N; Syed DN; Khan MI; Adhami VM; Mirza B; Mukhtar H
Oncotarget; 2016 Jan; 7(4):3819-31. PubMed ID: 26683363
[TBL] [Abstract][Full Text] [Related]
4. Triptonide acts as a novel antiprostate cancer agent mainly through inhibition of mTOR signaling pathway.
Dong F; Yang P; Wang R; Sun W; Zhang Y; Wang A; Chen M; Chen L; Zhang C; Jiang M
Prostate; 2019 Aug; 79(11):1284-1293. PubMed ID: 31212374
[TBL] [Abstract][Full Text] [Related]
5. Molecular signatures of sanguinarine in human pancreatic cancer cells: A large scale label-free comparative proteomics approach.
Singh CK; Kaur S; George J; Nihal M; Pellitteri Hahn MC; Scarlett CO; Ahmad N
Oncotarget; 2015 Apr; 6(12):10335-48. PubMed ID: 25929337
[TBL] [Abstract][Full Text] [Related]
6. Coatomer subunit beta 2 (COPB2), identified by label-free quantitative proteomics, regulates cell proliferation and apoptosis in human prostate carcinoma cells.
Mi Y; Sun C; Wei B; Sun F; Guo Y; Hu Q; Ding W; Zhu L; Xia G
Biochem Biophys Res Commun; 2018 Jan; 495(1):473-480. PubMed ID: 29129687
[TBL] [Abstract][Full Text] [Related]
7. Proteomic-based investigations on the mode of action of the marine anticancer compound rhizochalinin.
Dyshlovoy SA; Otte K; Venz S; Hauschild J; Junker H; Makarieva TN; Balabanov S; Alsdorf WH; Madanchi R; Honecker F; Bokemeyer C; Stonik VA; von Amsberg G
Proteomics; 2017 Jun; 17(11):. PubMed ID: 28445005
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
9. A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. I: In vitro studies.
Li L; Zhu Z; Joshi B; Porter AT; Tang DG
Anticancer Res; 1999; 19(1A):51-60. PubMed ID: 10226524
[TBL] [Abstract][Full Text] [Related]
10. Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells.
Qiu JX; Zhou ZW; He ZX; Zhao RJ; Zhang X; Yang L; Zhou SF; Mao ZF
Drug Des Devel Ther; 2015; 9():349-417. PubMed ID: 25609920
[TBL] [Abstract][Full Text] [Related]
11. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
12. An ion-current-based, comprehensive and reproducible proteomic strategy for comparative characterization of the cellular responses to novel anti-cancer agents in a prostate cell model.
Tu C; Li J; Bu Y; Hangauer D; Qu J
J Proteomics; 2012 Dec; 77():187-201. PubMed ID: 22982362
[TBL] [Abstract][Full Text] [Related]
13. The Proteome of Primary Prostate Cancer.
Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
[TBL] [Abstract][Full Text] [Related]
14. CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway.
Hung CM; Lin YC; Liu LC; Kuo SC; Ho CT; Way TD
Chem Biol Interact; 2016 Dec; 260():1-12. PubMed ID: 27769712
[TBL] [Abstract][Full Text] [Related]
15. Corosolic acid, a natural triterpenoid, induces ER stress-dependent apoptosis in human castration resistant prostate cancer cells via activation of IRE-1/JNK, PERK/CHOP and TRIB3.
Ma B; Zhang H; Wang Y; Zhao A; Zhu Z; Bao X; Sun Y; Li L; Zhang Q
J Exp Clin Cancer Res; 2018 Sep; 37(1):210. PubMed ID: 30176898
[TBL] [Abstract][Full Text] [Related]
16. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
Yan G; Ru Y; Wu K; Yan F; Wang Q; Wang J; Pan T; Zhang M; Han H; Li X; Zou L
Prostate; 2018 Feb; 78(3):166-177. PubMed ID: 29181846
[TBL] [Abstract][Full Text] [Related]
17. Target to apoptosis: a hopeful weapon for prostate cancer.
Tang DG; Porter AT
Prostate; 1997 Sep; 32(4):284-93. PubMed ID: 9288188
[TBL] [Abstract][Full Text] [Related]
18. A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer.
Byun WS; Jin M; Yu J; Kim WK; Song J; Chung HJ; Jeong LS; Lee SK
Biochem Pharmacol; 2018 Dec; 158():84-94. PubMed ID: 30292755
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive compound from cucumber, inhibits prostate cancer growth.
Gao Y; Islam MS; Tian J; Lui VW; Xiao D
Cancer Lett; 2014 Jul; 349(1):15-25. PubMed ID: 24690568
[TBL] [Abstract][Full Text] [Related]
20. Ursolic Acid Induces Apoptosis of Prostate Cancer Cells via the PI3K/Akt/mTOR Pathway.
Meng Y; Lin ZM; Ge N; Zhang DL; Huang J; Kong F
Am J Chin Med; 2015; 43(7):1471-86. PubMed ID: 26503559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]